Launch announcement

Sep 22, 2025

Microscope

Nuclide Therapeutics secures £5 million investment to spearhead the clinical development of our lead therapeutic, [131I]NTx-11.

‹ Latest press release

Connect with us

Email us, and keep updated on our clinical trial pipeline on LinkedIn.

Email us

Connect with us

Email us, and keep updated on our clinical trial pipeline on LinkedIn.

Email us

Multi colour gradient with abstract wave form

© 2026 Nuclide Therapeutics, All rights reserved

contact@nuclidetx.com

Designed & Built by Keetley Studio

Privacy Policy

Cookie Policy

Multi colour gradient with abstract wave form

© 2026 Nuclide Therapeutics, All rights reserved

contact@nuclidetx.com

Designed & Built by Keetley Studio

Privacy Policy

Cookie Policy

Multi colour gradient with abstract wave form

© 2026 Nuclide Therapeutics, All rights reserved

contact@nuclidetx.com

Designed & Built by Keetley Studio

Privacy Policy

Cookie Policy